Navigation Links
Hospira Reports Third-Quarter 2009 Results
Date:10/27/2009

slightly up.

During the third quarter, Hospira recognized an income tax benefit on the expiration of statutes of limitation on certain unrecognized tax benefits. The tax benefit was partially offset by the tax effect of the U.S. launch of oxaliplatin. Based on these factors, the company is adjusting the guidance for its 2009 effective tax rate to 20 to 21 percent from the prior guidance of 21 to 22 percent.

As a result, the company now expects full-year 2009 adjusted* diluted earnings per share to be between $2.85 and $2.90 per share. The reconciliation between the projected 2009 adjusted* diluted earnings per share and GAAP diluted earnings per share follows:

    Diluted earnings per share -- adjusted*                     $2.85 - $2.90
                                                                -------------
    Estimated charges related to Project Fuel
    initiatives (mid-point of an estimated range of
    $0.34 to $0.38 per diluted share for
    non-impairment charges, plus incurred
    year-to-date impairment and other asset
    charges of $0.37 per diluted share)                                ($0.73)

    Estimated charges related to facilities optimization
    initiatives (mid-point of an estimated range of
    $0.10 to $0.12 per diluted share)                                  ($0.11)

    Estimated $53 million for the amortization of
    intangibles related to the Mayne Pharma acquisition                ($0.23)

    Impairment of marketable equity securities                         ($0.10)

    Tax benefit from the settlement of a U.S. income tax audit          $0.57
                                                                -------------

    Diluted earnings per share -- GAAP                          $2.25 - $2.30
                                                                =============

The company now projects that cash flow from operations in 2009 will be in the $700 million to $750 million ran
'/>"/>

SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Voalte, the leader in ... in purpose-built wireless communications, today announced that Bay ... 104-bed acute-care facility in Webster, Texas ... One™ solution on Spectralink PIVOT™ purpose-built smartphones for ... Voalte a member of its AIMS Partner Program ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Pharmaceutical Industry in China to 2020: ... Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, ... offering. This report tackles not ... China but also home grown companies ...
(Date:7/28/2015)... YORK , July 28, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Human Insulin Market ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore ...
Breaking Medicine Technology:Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3Pharmaceutical Industry in China to 2020: Market to Increase Dramatically to $200 Billion 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
(Date:7/28/2015)... ... July 28, 2015 , ... Healthline , a provider of ... survey (1) examining consumers’ perspectives on digital health . The survey, which was ... as innovations in digital health, level of trust in the security of digital health ...
(Date:7/28/2015)... ... July 28, 2015 , ... opaJUMP! and O-PA! Performance ... health outcomes associated with its training methods. This company is also the first ... study, conducted in early 2015, training yielded an average 80% improvement in functional ...
(Date:7/28/2015)... ... July 28, 2015 , ... Egg freezing ... procedure to help ensure future fertility. As Dr. Michael Kettel explained in ... is an option that wasn’t available for previous generations who had to make choices ...
(Date:7/28/2015)... FL (PRWEB) , ... July 28, 2015 , ... On ... state officials refused to schedule the hearing of proposed bills and laws revolving the ... of new infections to date. Some vigilante ministers are continuing to hand out clean ...
(Date:7/28/2015)... ... 28, 2015 , ... Brookstone®, a nationwide specialty retailer and ... online product offerings, giving its customers the opportunity to straighten their teeth for ... patients to get quality, remote invisible aligner treatment from a state-licensed dental provider ...
Breaking Medicine News(10 mins):Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3
... ... dermatology with one of the highest honors in the industry. , ... (PRWEB) March 8, 2010 -- The Sturge-Weber Foundation honored renowned dermatologist Dr. ... Miami on March 05, 2010. Dr. Goldberg is a pioneer in the field ...
... , , ... ... ... , ...
... When treating cancer, it is an advantage to know the ... currently used to determine tumour growth, however, is erroneous. This ... Sweden, who have developed a new model. The ... of cancer cells through the body to form new tumours ...
... ... ... today announced a new line of door and wall protection products made from a blend ... in green innovation. The sustainable products will be sold at the same price level as ...
... vaccinate all children , MONDAY, March 8 (HealthDay News) -- ... B aren,t getting treatments that have been shown to prevent ... within 24 hours of birth, the hepatitis B vaccine and ... of newborns from becoming infected, even if they were exposed ...
... ... ... ... ...
Cached Medicine News:Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 2Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 3Health News:Alzheimer's Association Honors Social Security Commissioner Michael Astrue With Humanitarian Award 2Health News:Alzheimer's Association Honors Social Security Commissioner Michael Astrue With Humanitarian Award 3Health News:Alzheimer's Association Honors Social Security Commissioner Michael Astrue With Humanitarian Award 4Health News:InPro Launches Biopolymer PETG - Greenest Material for Div. 10 Products 2Health News:InPro Launches Biopolymer PETG - Greenest Material for Div. 10 Products 3Health News:1 in 5 At-Risk U.S. Babies Doesn't Get Hepatitis B Vaccine 2Health News:1 in 5 At-Risk U.S. Babies Doesn't Get Hepatitis B Vaccine 3Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 3Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 4Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: